{
    "Trade/Device Name(s)": [
        "Access CEA"
    ],
    "Submitter Information": "Beckman Coulter, Inc.",
    "510(k) Number": "K223921",
    "Predicate Device Reference 510(k) Number(s)": [
        "K991707",
        "K981985"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DHX"
    ],
    "Summary Letter Date": "September 22, 2023",
    "Summary Letter Received Date": "August 23, 2023",
    "Submission Date": "August 23, 2023",
    "Regulation Number(s)": [
        "21 CFR 866.6010"
    ],
    "Regulation Name(s)": [
        "Tumor-Associated Antigen Immunological Test System"
    ],
    "Analyte Class(es)": [
        "immunology",
        "cancer molecular"
    ],
    "Analyte(s)": [
        "Carcinoembryonic Antigen (CEA)"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "DxI 9000 Access Immunoassay Analyzer",
        "Access Immunoassay Systems",
        "Access 2 Immunoassay system"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent immunoassay",
        "Paramagnetic particle immunoassay",
        "Two-site immunoenzymatic sandwich assay"
    ],
    "Methodologies": [
        "Immunoenzymatic sandwich",
        "Chemiluminescence detection"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent kit"
    ],
    "Document Summary": "FDA 510(k) summary for Access CEA chemiluminescent immunoassay for quantitative measurement of carcinoembryonic antigen in human serum using Access Immunoassay Systems",
    "Indications for Use Summary": "Quantitative determination of Carcinoembryonic Antigen (CEA) levels in human serum as an aid in the management of cancer patients with observed changes in CEA concentrations",
    "fda_folder": "Immunology"
}